Although these adverse events are rare, further studies are needed to clarify the relationship between Ig replacement and immunomodulatory therapy and these adverse reactions

Although these adverse events are rare, further studies are needed to clarify the relationship between Ig replacement and immunomodulatory therapy and these adverse reactions. widely between countries. Dr Berger’s presentation on optimization of Ig therapy in neuropathies, and Dr Rojavin’s statement on a pharmacometric model to determine the serum IgG levels achieved by different dosing regimens in main antibody deficiency (PAD) patients, led to the challenging concept of using individualized dosing strategies. Dr Klehmet reported around the potential benefit of using antigen-specific T cell responses as a biomarker of IVIg responsiveness in Il6 CIDP patients, while Dr von Gunten provided an insight into the mechanisms of action of Ig preparations, suggesting that this immunoregulatory effects of IgG may be mediated by IgG antibodies against glycans. Dr Basta reported around the potential thrombogenic adverse effects associated with Ig therapy. Although these adverse events are rare, further studies are needed to clarify the relationship between Ig replacement and immunomodulatory therapy and these adverse reactions. In transplantation, Dr Carbone explained that prophylactic IVIg treatment was found to decrease the incidence of severe contamination in IgG hypogammaglobulinaemia patients undergoing heart transplantations. Furthermore, Dr Clatworthy reported that inactivating polymorphisms in the inhibitory receptor FcRIIB do not impact upon kidney allograft survival. Keywords:intravenous immunoglobulin, Fenipentol neuropathy, main immunodeficiency, subcutaneous immunoglobulin, transplantation == Introduction == Immunoglobulin (Ig) therapy is used to treat main immunodeficiency disorders (PIDs) and autoimmune and inflammatory diseases, and can potentially play a role in improving clinical outcomes in organ transplantation. This paper discusses the styles of Ig use in Europe, proposed mechanisms of action, adverse effects and novel uses for intravenous immunoglobulin (IVIg). The use and availability of IgG as replacement therapy in PID has Fenipentol been monitored via a pan-European survey established by the European Society for Immunodeficiencies (ESID) Main Immunodeficiencies Care in Development Working Party (PIDCD WP). Dr ediv discusses the styles observed in Ig use in Europe, noting that IVIg products are available in all European countries and the availability and usage of subcutaneous immunoglobulin (SCIg) products are increasing across Europe, although access to treatment for PID patients differs. Results of this survey also spotlight that, in some countries, IVIg preparations are used more commonly in adult populations and SCIg preparations are favoured in paediatric populations. Dr Berger reviews studies around the dosage of Ig therapy in chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN) patients, concluding that individualized dosing regimens may increase efficacy of treatment. In addition, better outcome steps assessed Fenipentol more frequently by patients themselves can be used to identify patients who would benefit from weekly SCIg rather than IVIg at 34-week intervals and those in whom IgG therapy is usually ineffective. Dr Rojavin has noted a shortage of guidance on the SCIg dosage and treatment duration for newly diagnosed main antibody deficiency (PAD) patients. In his presentation, Dr Rojavin explains the use of a pharmacometric model, based on data from SCIg and IVIg clinical trials, to test a range of loading regimens in PAD patients. Although Ig therapy is used for a variety of autoimmune and inflammatory conditions, the mechanism of action for Ig remains unclear. Previous studies have shown activated T cells in the blood of CIDP patients suggesting that autoreactive T cells against myelin antigens are important in the disease process. Dr Klehmet discusses results from an observational trial, which found that the immunomodulatory effects observed in long-term IVIg treatment responders are associated with a decrease in the autoreactive T cell response against peripheral myelin antigens in CIDP patients. In order to guideline rational use of IVIg/SCIg treatment, a better understanding of the observed Fenipentol mechanisms of action is needed. Dr von Gunten reports that IVIg/SCIg preparations contain a broad range of anti-carbohydrate IgG antibodies to many specific biologically relevant glycans that might contribute to the beneficial clinical effects witnessed with IVIg/SCIg therapy. The analysis of naturally occurring IgG specificities against glycans used by pathogens for host cell adhesion might be exploited for the design of potent glycovaccines. Dr Basta reports that thromboembolic events after IVIg infusions are rare, and postulates that IVIg may have a protective effect given the decrease of the incidence of stroke.